How Robocentric Biotech division operates
Subscribe: Apple Podcasts | Google Podcasts | Spotify | RSS | More
Producing and marketing biotech-made biomatter is one thing I’m after in Robocentric Biotech.
In order for something synthetic to sell, it must have superior performance and value than the natural counterpart, or more convenience.
So, via biotech, I’ll create packages of synthetic biomatter that are vastly superior in performance and value than the natural counterparts.
Robocentric biotech produces and uses the following product documents.
Biotech product value proposition document (with current and potential market data, reason[s] why people will buy and repeatedly use the benefit[s] provided by the biotech product) (if this doesn’t make sense, no going forward on this biotech product idea).
A quick advertisement before I continue on this topic. You can invest in my startup company with as little as US$100, for supporting advancing AI, robotics, biotech, and nuclear-fusion powered outer space tech. Visit Robocentric.com/Investors to invest in my startup.
I’ve a multidecadal commitment to advancing AI, robotics, biotech, and nuclear-fusion powered outer space tech. To learn more about my cause, check out my books, which are available at Robocentric.com/Checkout, Amazon, Apple Books, Spotify, and other online audiobook retailers. Now, back to the main content.
Biotech product spec sheet.
Biotech product marketing campaign spec.
Biotech product user manual.
Biotech product tech spec.
Biotech product patent application(s).
Robocentric researches, develops, and commercializes biomatter production biotech (biomatter production bio units or devices) (DNA, genome, cell component, cell, tissue, organ, limb, and whole body production biotechnologies) (for industrial, consumer, medical, and food-production biomatter. Constant R&D on this, along with constant R&D on all the other core biotechnologies.)
Robocentric researches, develops, and commercializes human food production biotech (milk, eggs, meat, etc.) (Genetically engineered asexual or non-reproductive human food animals and plants, human-food animal and plant medical biotech.)
Robocentric Biotech division operates in the two main Robocentric Biotech operation areas.
Constant core biotech R&D with the intention to eventually commercialize, and to eventually realize the human longevity biotech, the human body manufacturing and replacement biotech, and the medical and cosmetic and behavioral human genetic engineering biotech.
Core biotech productization or applied biotech product development and marketing, in all Robocentric biotech product categories (such as human and nonhuman medical biomatter packages), when there’s a sufficient biotech product value proposition. However, even with a sufficient biotech product value proposition, a biotech product may fail to sell in the market: constant biotech commercialization effort is required for producing hit biotech products.
Robocentric core and applied biotech development involves AWA (Animal Welfare Act) and non-AWA covered animal tests with extensive documentation and publication.
Human and nonhuman food plant and animal farming, processing, and waste processing biotech products (I think animal waste processing biotech can be a multibillion-dollar industry, since humans constantly grow animals globally for food consumption. I’ll get into it.)
You can invest in my startup company with as little as US$100, for supporting advancing AI, robotics, biotech, and nuclear-fusion powered outer space tech. Visit Robocentric.com/Investors to invest in my startup.
My books on advancing AI, robotics, biotech, and nuclear-fusion powered outer space tech are available at Robocentric.com/Checkout, Amazon, Apple Books, Spotify, Google Play Store, and other online audiobook retailers.
I am Allen Young; I’m an Asian-American man who focuses on advancing AI, robotics, human longevity biotech, and nuclear-fusion powered outer space tech.
